Among other things, the agency explains that DDIs are a critical factor in a drug’s overall benefit-risk profile. The results of in vitro #DDI studies and pharmacokinetic (PK) data “provide mechanistic information that can inform the need for and proper design of potential future clinical studies.” More information here.
Meet us at BioAsia 2020 in India
Category: news
ReadyCell is happy to announce that its tean will be attending this year’s BioAsia Conference taking place from 17 – 19 February 2020 in Hyderabad, India. If you want to meet us there, contact us! BioAsia is a comprehensive framework dedicated to investors, researchers, start-ups, conglomerates in biotechnology, pharma and healthcare to bring them at one stage. The aim is to create business paradigms for the ever-evolving needs of the Lifesciences industry. It is an
We are hiring a Business Developer
Category: news
Readycell, desarrolla, implementa y comercializa kits de base celular, preparados para su uso, que aportan análisis con un alto nivel de fiabilidad, reduciendo tiempo y costes, y permitiendo que las compañías farmacéuticas y biotecnológicas que lo utilizan puedan utilizar sus recursos tanto materiales como humanos de una forma más eficiente, optimizando a su vez el ciclo de desarrollo para nuevas investigaciones. Nuestro departamento de I&D trabaja en la expansión de nuestro portfolio de productos, con
ReadyCell S.L. was proud to recently welcome our colleagues and partners from SOLVO Biotechnology to our facilities in the Barcelona Science Park. SOLVO Biotechnology is a leading provider of transporter services and products for pharmaceutical, biotechnological, and CRO companies. We had the pleasure to welcome their representatives Nóra Kormos, Nikoletta Geltsch and Zsolt Fekete to discuss different topics related to quality, commercial, and new collaboration scenarios.
And more news related to the expansion of ReadyCell in Asia: For the first time in the history of ReadyCell S.L., we have completed a successful shipment to China from our facilities in Spain. China is definitely a potential market for Drug Discovery, and we are glad to say that we are building and consolidating relevant partnerships in order to increase our presence and technologies in one of the biggest economies worldwide. Every time more than